louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03235648: Evaluation of Surgical Excision of Cardiophrenic Lymph Nodes in Patients With Advanced Ovarian Cancer
Official title: Evaluation of Surgical Excision of Cardiophrenic Lymph Nodes in Patients With Advanced Ovarian Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Ovarian Cancer
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2017-08-01
Enrollment: 25
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Evaluation of surgical excision of cardiophrenic lymph nodes in patients with advanced ovarian cancer

Detailed description: The role of cardiophrenic lymph node assessment and excision in advanced ovarian cancer is still debatable , correlation of radiological finding with pathological findings after reaction of radiological positive lymph nodes and its impact in diseases free survival and over all survival

Eligibility criteria: Inclusion criteria

* Ovarian cancer patient (FIGO stage III-IV)
* Preoperative CT showing CPLN with short axis diameter \> 5mm.
* Anathestically fit patient (ASA score I or II).
* Accepted pulmonary function test.
* Patient who received neoadjuvant chemotherapy or recurrent cases may be enrolled
* Written informed consent.
* Achievement of optimal cytoreduction intra-abdominal( No residual disease more than 1 cm )

Exclusion Criteria:

* Anathestically unfit patient
* Unresectable disease
* Patient refusal
* No detected CPLN by preoperative radiology

Primary outcomes:
measure: number of CPN retrieved/pathological nodes
timeFrame: up to 3 years
Secondary outcomes:
measure: Progression free survival
timeFrame: up to 2 years following the end of study
Other outcomes:
measure: Overall survival
timeFrame: up to 2 years following the end of study
Locations:
city: Cairo
country: Egypt
facility: Oncology center, Mansoura University
state: Dakhlia
Study officials:
References:
Clinical trial NCT05088148: Comparison of Pesticide and Pharmaceutical Contaminants Levels in Placenta and Cord Blood Samples of Pregnant Women With Fetal Growth Retardation and Healthy Pregnant Women
Official title: Comparison of Pesticide and Pharmaceutical Contaminants Levels in Placenta and Cord Blood Samples of Pregnant Women With Fetal Growth Retardation and Healthy Pregnant Women
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Fetal Growth Retardation
Lead sponsor: Kutahya Health Sciences University
Sponsor class: OTHER
First posted: 2021-10-21
Enrollment: 40
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study will be conducted with a total of 40 pregnant women, 20 of whom are in the control groups and those with FGR diagnoses. Cases in both groups will be matched in terms of demographic information. Demographic information (including socioeconomic status, educational level, region of residence), ultrasound and Doppler examination results, newborn weight at birth, APGAR score, gender, mode of delivery, whether there is a need for neonatal intensive care or not will be recorded.

Brief summary: Aim: In this study, pesticide and pharmaceutical contaminants levels in the placenta and cord blood of pregnant women with fetal growth retardation and healthy pregnant women will be compared in placenta and cord blood samples after delivery.

Detailed description: The study will be conducted with a total of 40 pregnant women, 20 of whom are in the control groups and those with FGR diagnoses. Cases in both groups will be matched in terms of demographic information. Demographic information (including socioeconomic status, educational level, region of residence), ultrasound and Doppler examination results, newborn weight at birth, APGAR score, gender, mode of delivery, whether there is a need for neonatal intensive care or not will be recorded.

Eligibility criteria: Inclusion Criteria:

* Between the ages of 18-40 years
* Gestational age between 320/7 - 396/7 weeks
* Singleton pregnancy
* For the FGR group: estimated fetal weight \<10th percentile
* For the control group: being healthy pregnant
* Intact amniotic membrane

Exclusion Criteria:

* Multiple pregnancies
* Cardiovascular disease
* Chronic hypertension
* Autoimmune disease
* Intrahepatic cholestasis of pregnancy
* Preeclampsia-eclampsia
* Sepsis
* Placenta accreta spectrum
* Abnormalities of placenta
* The chromosomal or congenital structural anomaly of the fetus
* Smoking
* BMI \>30 kg/m2

Primary outcomes:
measure: Pesticide and Pharmaceutical analysis
timeFrame: 1 year
Secondary outcomes:
measure: Multi logistic regression analysis.
timeFrame: 1 month
measure: ROC analysis
timeFrame: 1 month
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00474448: The Health-Related Quality of Life in Patients With Hereditary Multiple Exostoses
Official title: The Health-Related Quality of Life in Patients With Hereditary Multiple Exostoses
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Exostoses, Multiple Hereditary
Keywords: Hereditary Multiple Exostoses
Survey
Quality of Life
Hereditary Multiple Exostoses,
also known as Multiple Hereditary Exostoses,
also known as Hereditary Multiple Osteochondromas
Lead sponsor: University of British Columbia
Sponsor class: OTHER
Collaborators: name: MHE Coalition
First posted: 2007-05-17
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients or parents of child patients in British Columbia.

Brief summary: The purpose of this study is to assess the health-related quality of life of subjects who have Hereditary Multiple Exostoses and to develop a disease specific quality of life survey. The investigators hypothesize that there are a wide range of quality of life experiences for patients with this syndrome.

Detailed description: At the time of recruitment, subjects will be asked to indicate whether they would like to participate in a one-time survey, or are willing to participate in the initial survey plus two additional questionnaire administrations, thereafter, which will be used to develop the disease-specific quality of life (QOL) score. All participants will complete either the SF-36 survey (for adult HME subjects) or the CHQ PF (for parents of children with HME), as applicable, in addition to a blank form with categorical subheadings (such as recreation, social function, etc.), which they will use to address any issues not covered in the standardized questionnaire. Standardized questionnaires will be scored and analyzed. The items listed on the second form will be compiled and reapplied to subjects that indicated interest in extended participation in survey completion. Subjects will be asked to determine which items apply to them and to rank these applicable items in order of importance. The results from this will be used to develop a 30 question, disease-specific questionnaire. The final step will be to readminister this survey, in conjunction with the SF-36 or CHQ PF, and follow up, in two weeks, with a second administration of the aforementioned surveys, in order to test the variability and validity of the disease-specific, health-related, quality of life score.

Eligibility criteria: Inclusion Criteria:

* Must be diagnosed with Hereditary Multiple Exostoses
* Adult patients or parents of child patients

Primary outcomes:
measure: SF-36 score for adults and CHQ PF-50 for children
timeFrame: No time frame
Secondary outcomes:
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: BC Children's Hospital
state: British Columbia
Study officials:
affiliation: University of British Columbia
name: Christine Alvarez, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05731648: Role of Functional Neurosurgery in Management of Spasticity
Official title: Role of Functional Neurosurgery in Management of Spasticity
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Functional Neurological Disorder
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2023-02-16
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Spasticity

Brief summary: Spasticity can result from a variety of causes in neural axis from which most common are cerebral palsy, strokes, cerebral haemorrhage, multiple sclerosis , traumatic brain injury and spinal cord injury and underlying mechanism is broadly due to decrease inhibition of the spinal network.

Clinical evaluation for spasticity involve series of clinical assessment , physical examination , and neurophysiological testing. quantitative evaluation of spasticity can be measured using modified Ashworth scale which is the most widely used clinical spasticity scale and can be used for various clinical conditions causing spasticity

Detailed description: Currently, the management of spasticity spans in a continuum between non-invasive and invasive intervention to modulate its effects and improve patients' Quality of life and when spasticity becomes excessive and aggravates disability, functional neurosurgery can be a resource.

Neurosurgical procedures for management of spasticity are classified according to whether their effect is generalized or focal and whether they are reversible or irreversible. Procedures include intrathecal baclofen pump , spinal cord stimulation and lesioning techniques peripheral nerves , dorsal roots , spinal cord or dorsal root entry zone

Eligibility criteria: Inclusion Criteria:

* Patients with spasticity refractory to medical treatment (most commonly administered oral medications for managing spasticity are diazepam, dantrolene sodium, and baclofen) and physiotherapy

Exclusion Criteria:

* Patients unfit for neurosurgical intervention

Primary outcomes:
measure: Evaluate safety and efficacy of neurosurgical procedures
timeFrame: 6 month
measure: Evaluate Changes in Modified Ashworth scale
timeFrame: 6 month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Hinderer SR, Dixon K. Physiologic and clinical monitoring of spastic hypertonia. Phys Med Rehabil Clin N Am. 2001 Nov;12(4):733-46.
citation: Kheder A, Nair KP. Spasticity: pathophysiology, evaluation and management. Pract Neurol. 2012 Oct;12(5):289-98. doi: 10.1136/practneurol-2011-000155.
Clinical trial NCT06346548: Study on the Chromatic Perception of Digital Systems in Aesthetic Field
Official title: Monocentric Observational Cross-sectional Study on the Chromatic Perception of Digital Systems in Aesthetic Field
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Color Detection of Upper Central Incisors
Lead sponsor: IRCCS San Raffaele
Sponsor class: OTHER
First posted: 2024-04-04
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: As part of normal clinical practice, the expected population for the examination (anticipated number of patients = 78) will undergo three different chromatic detection methodologies to assess differences in chromatic perception through intra and inter group analyses. The selected sample will be divided equally only based on three different age groups (18-29 years, 30-59 years, \>60 years).

Brief summary: The study under consideration aims to evaluate differences in chromatic perception among three distinct color acquisition methodologies. Specifically, recruited patients will undergo testing with three different color detection systems, including two intraoral photography methodologies and one digital intra oral scanning. All procedures conducted are part of normal clinical practice.


Eligibility criteria: Inclusion Criteria:

* Patients with good oral health
* Age over 18 years old
* Signing of an informed consent form according to the protocol

Exclusion Criteria:

* Any type of restoration on the upper central and lateral incisors

Primary outcomes:
measure: Comparison of chromatic values of the upper central incisors
timeFrame: 9 months
Secondary outcomes:
Other outcomes:
Locations:
city: Milano
country: Italy
facility: IRCCS San Raffaele
Study officials:
affiliation: IRCCS San Raffaele
name: Paolone Gaetano
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00412048: Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease
Official title: Evaluation of fMRI-SAM in the Early Detection of Alzheimer's Disease.
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Alzheimer's Disease
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2006-12-15
Enrollment: 0
Sex: ALL
Minimum age (years): 55
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The aim of the protocol is to study the resting brain activation profile of 3 groups of people, using a new fMRI procedure, called fMRI-SAM. fMRI-SAM will be applied to 25 Alzheimer's disease (AD) patients, 25 patients suffering from amnestic - mild cognitive impairment (MCI) - a clinical picture which may be a prodromal form of AD - and 60 healthy controls. The first analysis of the data will search differences of brain activation profiles between the 3 groups. In the second step, the investigators will study the predictive value of fMRI-SAM to detect MCI patients who will later convert to AD.


Eligibility criteria: Inclusion criteria:

* Alzheimer's disease of mild to moderate severity (25 patients)
* Amnestic MCI patients (25 patients)
* 55-75 year-old patients

Exclusion criteria:

* Any other cause of dementia for AD patients
* Any stroke
* Any disease with a negative vital prognosis

Primary outcomes:
measure: Comparing fMRI data between 3 groups of subjects: MCI, Alzheimer's disease and normal subjects
timeFrame: 1, 5 years
Secondary outcomes:
measure: Follow-up of MCI patients at 6, 12 and 18 months to detect a conversion to Alzheimer's disease
timeFrame: Prediction of Alzheimer's disease on fMRI data
Other outcomes:
Locations:
Study officials:
affiliation: Hôpitaux Universitaires de Strasbourg
name: Francois Sellal, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00651248: Evaluation of Salivary Flow and Buffer Capacity Associated to Aged People's Oral Health
Official title: Evaluation of Salivary Flow and Buffer Capacity Associated to Aged People's Oral Health
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Oral Health
Diagnosis, Oral
Public Health
Keywords: Saliva
Oral health
Aged
Lead sponsor: Academia Cearense de Odontologia
Sponsor class: OTHER
First posted: 2008-04-02
Enrollment: 68
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Sampling method: PROBABILITY_SAMPLE
Study population: 68 aged, average 70.4 years, SD ± 7.27 represented institution's residents of long permanence.

Brief summary: The purpose of this study is to identify the relation of the salivary flow and the buffer capacity of the saliva with medicine, buccal discomfort and auto-related illnesses in aged people.

Detailed description: Study clinical of prevalence. 68 aged, average 70.4 years, SD ± 7.27 represented institution's residents of long permanence. Questionnaire was applied, organizing the data for Software SPSS version 15. The test qui-square of Pearson was used, level of significance 5% and reliable interval 95%. 80% presented pH normal. The salivary Flow: 32.3% very low, 41.2% reduced and 25.5% normal. 30.9% mentioned dry mouth, 22.1% tasting's problems, 17.6% dysphagia and 14.7% burning mouth. Main systemic illnesses: 48.5% declared cardiovascular problems, 17.6% diabetes and 16.2% osteoporosis. 76.5% used medicine. There was a significance statistic between medicine taking and dry mouth (p=0.013), buffer capacity and burning mouth (p=0.019), salivary flow and medicine taking (p=0.048). The low salivary flow and the buffer capacity of the saliva influence in the aged people's health condition, as the drugs influence the results.

Eligibility criteria: Inclusion Criteria:

* aged people with 60 years old or more,
* ills or not,
* able to realize tests
* people who want to participate of research

Exclusion Criteria:

* people less 60 years old

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Fortaleza
country: Brazil
facility: Instituição de Longa Permanência Lar Torres de Melo
state: Ceara
Study officials:
affiliation: Universidade de Fortaleza
name: Maria VL Saintrain, doutor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02047448: Improving Medication Adherence Through a Transitional Care Pharmacy Practice Model
Official title: Improving Medication Adherence Through a Transitional Care Pharmacy Practice Model
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Pulmonary Disease, Chronic Obstructive
Heart Failure
Keywords: transition of care
care transitions
readmission
medication
adherence
medication management
medication reconciliation
patient counseling
pharmacist
Lead sponsor: Wilkes University
Sponsor class: OTHER
Collaborators: name: Moses Taylor Hospital Foundation
name: Commonwealth Health
name: Community Pharmacy Foundation
First posted: 2014-01-28
Enrollment: 180
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this pilot study is to determine if medication adherence is improved by a transitional care pharmacy practice model designed to integrate hospital and community pharmacists in the care and education of patients with heart failure or COPD who are discharged from a community hospital to home. The hospital and community pharmacists will collaborate with each other, the patient, and other practitioners including the primary care physician, nurse, and case manager to prevent and correct medication-related problems and attempt to improve patient outcomes especially during the error-prone transition from hospital to home.


Eligibility criteria: Inclusion Criteria:

* admitted to hospital with a primary or secondary diagnosis of heart failure or COPD
* anticipated eventual discharge to home
* agreeable to participate in monthly counseling sessions (if randomized to intervention group) from a participating community pharmacist

Exclusion Criteria:

* presence of cognitive impairment or dementia that would significantly prevent effective patient education and counseling
* non English-speaking
* anticipated discharge to a long-term care or skilled nursing facility on a permanent basis
* permanent long-term care facility residents
* surgical patients
* hospice patients
* patients who die within 30 days of initial study hospitalization

Primary outcomes:
measure: Medication Adherence
timeFrame: 6 months
Secondary outcomes:
measure: Medication related problems
timeFrame: 6 months
measure: Patient Satisfaction
timeFrame: 6 months
measure: Hospital readmissions or ED visits
timeFrame: 6 months
Other outcomes:
Locations:
city: Scranton
country: United States
facility: Moses Taylor Hospital
state: Pennsylvania
Study officials:
affiliation: Wilkes University
name: Judith Kristeller, PharmD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01731548: A Prospective Randomized Study Comparing the Target Volume for Limited-stage Small Cell Lung Cancer
Official title: Omitting Elective Nodal Irradiation and Irradiating Post-induction Versus Pre-induction Chemotherapy Tumor Extent for Limited-stage Small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Carcinoma of Lung
Small Cell
Limited Stage
Lead sponsor: Zhejiang Cancer Hospital
Sponsor class: OTHER
Collaborators: name: Sun Yat-sen University
First posted: 2012-11-21
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: We hypothesized that the local control for both arms were not statistically significant, when irradiation to the post-induction chemotherapy tumor volume is compared with irradiation to the pre-induction chemotherapy tumor volume.While elective nodal irradiation will be omitted for both arms.


Eligibility criteria: Inclusion Criteria:

* Patients were eligible if they had histologic or cytologic verification of small cell lung cancer (SCLC) and were radiographically confirmed limited-stage
* Patients with contralateral mediastinal and ipsilateral supraclavicular lymphadenopathy were also included.
* The patients should be between 18 and 75 years old without previous thoracic radiotherapy, chemotherapy or biotherapy.
* Karnofsky performance status was ≥ 80.
* Forced expiratory volume at 1 second (FEV1) ≥ 1 L.
* Had measurable or assessable disease.
* Neutrophilic granulocyte ≥ 1.5×109/L, haemoglobin ≥ 100 g/L, platelet count ≥ 100×109/L.
* Serum creatine and bilirubin \< 1.5 × the upper normal limit (UNL), aminotransferase \< 2 × UNL.
* Weight loss was less than 10% within 6 months before diagnosis.
* Written informed consent was required from all patients.

Exclusion Criteria:

* Patients were ineligible if they had a history of other malignant diseases except for non-melanomatous skin cancer and carcinoma in situ of the cervix, or any contraindications for chemoradiotherapy, malignant pleural and/or pericardial effusion.

Primary outcomes:
measure: local-regional progression
timeFrame: at least 6 months
Secondary outcomes:
measure: overall survival
timeFrame: at least 1 year
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-Sen University, Cancer Center
state: Guangdong
Study officials:
affiliation: Zhejiang Cancer Hospital
name: Ming Chen, MD
role: PRINCIPAL_INVESTIGATOR
References: